Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
06 04 2023
Historique:
received: 14 09 2021
accepted: 15 02 2022
medline: 3 4 2023
pubmed: 15 3 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

Following the global declaration of indigenous wild poliovirus type 2 eradication in 2015, the world switched to oral polio vaccine (OPV) that removed the type 2 component. This 'switch' included the widespread introduction of inactivated poliovirus vaccine and the creation of a stockpile of monovalent type 2 OPV (mOPV2) to respond to potential polio virus Type 2 (PV2) outbreaks and events. With subsequent detection of outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), it was necessary to use this stockpile for outbreak response. Not only were more outbreaks detected than anticipated in the first few years after the switch, but the number of supplemental immunization activities (SIAs) used to stop transmission was often high, and in many cases did not stop wider transmission. Use of mOPV type 2 led in some locations to the emergence of new outbreaks that required further use of the vaccine from the stockpile. In the following years, stockpile management became a critical element of the cVDPV2 outbreak response strategy and continued to evolve to include trivalent OPV and genetically stabilized 'novel OPV type 2' vaccines in the stockpile. An overview of this process and its evolution is presented to highlight several of these management challenges. The unpredictable vaccine demand, fixed production and procurement timelines, resource requirements, and multiple vaccine types contributes to the complexity of assuring appropriate vaccine availability for this critical programmatic need to stop outbreaks.

Identifiants

pubmed: 35282924
pii: S0264-410X(22)00204-3
doi: 10.1016/j.vaccine.2022.02.058
pmc: PMC10427718
pii:
doi:

Substances chimiques

Poliovirus Vaccine, Oral 0
Poliovirus Vaccine, Inactivated 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

A70-A78

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Risk Anal. 2013 Apr;33(4):647-63
pubmed: 22985171
Expert Rev Vaccines. 2018 Aug;17(8):739-751
pubmed: 30056767
BMC Infect Dis. 2016 Mar 24;16:137
pubmed: 27009272
Lancet. 2019 Jul 13;394(10193):148-158
pubmed: 31174831
Lancet. 2021 Jan 2;397(10268):27-38
pubmed: 33308427
Lancet. 2021 Jan 2;397(10268):39-50
pubmed: 33308429
Risk Anal. 2021 Feb;41(2):329-348
pubmed: 33174263

Auteurs

Vachagan Harutyunyan (V)

World Health Organization, Geneva, Switzerland. Electronic address: harutyunyanv@who.int.

Arshad Quddus (A)

World Health Organization, Geneva, Switzerland.

Mark Pallansch (M)

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Simona Zipursky (S)

World Health Organization, Geneva, Switzerland.

David Woods (D)

World Health Organization, Geneva, Switzerland.

Ann Ottosen (A)

UNICEF Supply Division, Copenhagen, Denmark.

John Vertefeuille (J)

Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Ian Lewis (I)

UNICEF Supply Division, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH